Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480164 | 0.98 | CYP3A4 (0.35) | CYP3A4SMYD2HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL2481872 | 0.98 | CYP3A4 (0.35) | CYP3A4SMYD2HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL13794147 | 0.98 | CYP3A4 (0.35) | CYP3A4SMYD2HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL30158833 | 0.98 | CYP3A4 (0.35) | CYP3A4SMYD2HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL16878895 | 0.98 | CYP3A4 (0.35) | CYP3A4SMYD2HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL13295612 | 0.98 | CYP3A4 (0.35) | CYP3A4SMYD2HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL3456559 | 0.95 | SMYD2 (0.36) | CYP3A4SMYD2HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL2188878 | 0.89 | SMYD2 (0.37) | CYP3A4SMYD2HTTSMN1; SMN2MEN1 | |
| SCHEMBL2484114 | 0.84 | SMYD2 (0.35) | CYP3A4SMYD2HTTSMN1; SMN2 | |
| SCHEMBL15686013 | 0.82 | LTA4H (0.36) | CYP3A4SMYD2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2025-01-30 | — | — | US | disclosed |
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2024-02-08 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2020-01-30 | — | — | US | disclosed |
| US-20180104220-A1 | IMIDAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2018-04-19 | — | — | US | disclosed |
| EP-3287453-A1 | IMIDAZOLE COMPOUND | Medshine Discovery Inc. (CN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017156164-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170008918-A1 | NOVEL CYP-EICOSANOID DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-12 | — | — | US | disclosed |
| WO-2016169514-A1 | IMIDAZOLE COMPOUND | 广东众生药业股份有限公司 | 2016-10-27 | — | — | WO | disclosed |
| US-9127027-B2 | Epoxyeicosatrienoic acid analogs and methods of making and using the same | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140113884-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| US-20140113884-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| EP-2694470-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | M.C.W. Research Foundation, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012138706-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | MCW RESEARCH FOUNDATION, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-7732470-B2 | Compositions and methods for the treatment of renal and cardiovascular disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1315709-B1 | AMINOALKYLBENZOYL-BENZOFURAN OR BENZOTHIOPHENE DERIVATIVES, METHOD FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2010-05-26 | — | — | EP | disclosed |
| US-20080153889-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | 2008-06-26 | — | — | US | disclosed |
| US-6949583-B2 | Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same | SANOFI-SYNTHELABO (FR) | 2005-09-27 | — | — | US | disclosed |
| US-20030225100-A1 | Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same | SANOFI (FR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153889-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | REN, ALOX5, ALOX15B | CYP3A4 715/4885SMYD2 2672/4885HTT 3120/4885 |
| US-20170008918-A1 | NOVEL CYP-EICOSANOID DERIVATIVES | CYP4F3, ALOX5, CYP4A11 | CYP3A4 65/4885SMYD2 4593/4885HTT 4867/4885 |
| US-20030225100-A1 | Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same | NR2C2, NR4A2, NR5A2 | CYP3A4 342/4885SMYD2 1600/4885HTT 3568/4885 |
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | CYP3A4 3658/4885SMYD2 4633/4885HTT 362/4885 |
| US-20180104220-A1 | IMIDAZOLE COMPOUND | MAPT, SLC10A2, SLC5A11 | CYP3A4 42/4885SMYD2 3771/4885HTT 1232/4885 |
| US-20140113884-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | PTGER1, PTGES, PTGER2 | CYP3A4 190/4885SMYD2 3726/4885HTT 3423/4885 |
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | CYP3A4 3658/4885SMYD2 4633/4885HTT 362/4885 |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | CYP3A4 3658/4885SMYD2 4633/4885HTT 362/4885 |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | GPR55, GPR65, GPR35 | CYP3A4 3658/4885SMYD2 4633/4885HTT 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.